SNY changes
Pick any two versions below to diff them.
- Price
- $40.29 → $40.61(+0.8%)
- Recent events
- Oct added: 20, 2026: Sanofi and Teva showed 44-week data from the phase 2b extension study of duvakitug, their TL1A antibody, in ulcerative colitis and Crohn's disease. At the higher dose, 58% of ulcerative colitis patients were in clinical remission, and 55% of Crohn's disease patients had an endoscopic response. The study was small, and the companies call the data descriptive. Phase 3 studies continue in both diseases. Oct 1, 2026: Sanofi and Regeneron added four long-acting immunology antibodies to their alliance, among them REGN20423, an IL-13 antibody in phase 1. Regeneron receives $1 billion upfront and up to $7 billion in milestone payments, and the companies share costs and profits equally. Sep 14, 2026: Sanofi and Cheplapharm announced a plan under which Cheplapharm takes over 20 mature medicines, including the manufacture of Lovenox, and three manufacturing sites. In return, Sanofi receives a 26.4% equity stake in Cheplapharm. Jul 30, 2026: Sanofi reported Q2 2026 results. Sales rose 17.8% at constant exchange rates to €11,597 million, and Dupixent sales rose 37.6% to €5.2 billion. Business EPS rose 33.3% to €2.09, but IFRS EPS fell to €0.29 because of impairments. Sanofi raised its 2026 sales growth guidance to about 10% and said it expects Dupixent sales of about €25 billion in 2030. It completed its €1 billion share buyback. Jul 24, 2026: Sanofi stopped the development of amlitelimab in atopic dermatitis and will not submit it for approval, because it would not be a meaningful improvement over the standard of care. Sanofi also stopped the development of itepekimab and balinatunfib. Jul 21, 2026: Sanofi named a new, smaller Executive Committee from September 1, 2026. Olivier Charmeil left his role as head of General Medicines, and the General Counsel left the company. Jun 13, 2026: The FDA approved Tzield as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes. Apr 29, 2026: Shareholders appointed Belén Garijo as a director, and she became CEO of Sanofi. Olivier Charmeil had been interim CEO after Paul Hudson left in February 2026. Apr 23, 2026: Sanofi reported Q1 2026 results. Sales rose 13.6% at constant exchange rates to €10,509 million, Dupixent sales rose 30.8% to €4.2 billion, and business EPS rose 14.0% to €1.88. It completed the purchase of Dynavax.